CG
IMCR icon

Cutler Group’s Immunocore IMCR Stock Holding History

Cutler Group’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,500
Closed -$2K – 2884
2023
Q4 		$2K Buy
+2,500
New +$130K ﹤0.01% 3113
2023
Q2 		– Sell
-2,200
Closed -$34K – 3853
2023
Q1 		$34K Buy
+2,200
New +$124K ﹤0.01% 1591

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Cutler Group's IMCR Position: Q2 2023 in Review

Cutler Group sold out of Immunocore (IMCR) in Q2 2023, closing a stake of 1,780 shares — an estimated $102K sold.

Cutler Group first reported a position in IMCR in Q1 2023 and held it in 1 quarter. The position peaked at $88K in Q1 2023. 120 funds tracked by Wall St. Rank hold IMCR as of Q2 2023.

  • Cutler Group reported no remaining Immunocore position as of Q2 2023 after selling out during the quarter.
  • Cutler Group sold 1,780 Immunocore shares in Q2 2023, an estimated $102K.
  • Cutler Group first reported a position in Immunocore in Q1 2023 and held it in 1 quarter.
  • Cutler Group's Immunocore position peaked at $88K in Q1 2023.
  • 120 funds tracked by Wall St. Rank held Immunocore as of Q2 2023.

Based on Cutler Group's 13F filing for Q2 2023, filed 18 Jul 2023.